Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below 200 Day Moving Average of $7.47

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $7.47 and traded as low as $4.57. Eagle Pharmaceuticals shares last traded at $4.69, with a volume of 161,336 shares changing hands.

Eagle Pharmaceuticals Stock Up 2.1 %

The company has a 50-day moving average price of $5.54 and a two-hundred day moving average price of $7.37. The stock has a market capitalization of $58.20 million, a P/E ratio of 3.80 and a beta of 0.41.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of EGRX. Millennium Management LLC increased its position in shares of Eagle Pharmaceuticals by 2,428.4% during the second quarter. Millennium Management LLC now owns 314,739 shares of the specialty pharmaceutical company’s stock valued at $13,984,000 after buying an additional 302,291 shares during the period. Brandes Investment Partners LP increased its position in shares of Eagle Pharmaceuticals by 34.9% in the third quarter. Brandes Investment Partners LP now owns 1,134,363 shares of the specialty pharmaceutical company’s stock worth $17,889,000 after purchasing an additional 293,276 shares during the last quarter. Bank of America Corp DE increased its position in shares of Eagle Pharmaceuticals by 676.4% in the first quarter. Bank of America Corp DE now owns 318,174 shares of the specialty pharmaceutical company’s stock worth $9,027,000 after purchasing an additional 277,192 shares during the last quarter. State Street Corp increased its position in shares of Eagle Pharmaceuticals by 30.4% in the third quarter. State Street Corp now owns 1,011,747 shares of the specialty pharmaceutical company’s stock worth $26,730,000 after purchasing an additional 235,887 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Eagle Pharmaceuticals by 96.1% in the first quarter. AQR Capital Management LLC now owns 265,420 shares of the specialty pharmaceutical company’s stock worth $7,530,000 after purchasing an additional 130,105 shares during the last quarter. 85.36% of the stock is currently owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.